.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Chinese Patent Office
Queensland Health
Accenture
AstraZeneca
Fuji
Colorcon
Novartis
Mallinckrodt
Argus Health

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020201

« Back to Dashboard
NDA 020201 describes DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, which is a drug marketed by Hospira and Baxter Hlthcare and is included in two NDAs. It is available from three suppliers. Additional details are available on the DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER profile page.

The generic ingredient in DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER is dobutamine hydrochloride. There are fourteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the dobutamine hydrochloride profile page.

Summary for 020201

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 020201

Mechanism of ActionAdrenergic beta-Agonists

Medical Subject Heading (MeSH) Categories for 020201

Suppliers and Packaging for NDA: 020201

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
dobutamine hydrochloride
INJECTABLE;INJECTION 020201 NDA Hospira, Inc. 0409-2346 0409-2346-32 12 POUCH in 1 CASE (0409-2346-32) > 1 BAG in 1 POUCH > 250 mL in 1 BAG
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
dobutamine hydrochloride
INJECTABLE;INJECTION 020201 NDA Hospira, Inc. 0409-2347 0409-2347-32 12 POUCH in 1 CASE (0409-2347-32) > 1 BAG in 1 POUCH > 250 mL in 1 BAG

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 200MG BASE/100ML
Approval Date:Oct 19, 1993TE:APRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 100MG BASE/100ML
Approval Date:Oct 19, 1993TE:APRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 50MG BASE/100ML
Approval Date:Oct 19, 1993TE:APRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Queensland Health
Chinese Patent Office
Accenture
Cipla
Mallinckrodt
Medtronic
Fuji
Merck
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot